Milestone: Chemotherapy agent sends leukemia into remission
Date: Dec. 6, 1954
Where: Sloan Kettering Institute, New York
Who: Gertrude Elion and colleagues
In 1954, researchers introduced a groundbreaking drug that helped children with acute leukemia. This medication marked a significant step in chemotherapy and led to a new, smarter way of designing drugs.
Gertrude Elion, who faced many challenges in her career because she was a woman, started as a high school chemistry teacher. Despite her master’s degree in chemistry, she struggled to find research positions. In 1944, she began working in George Hitchings’s lab at Burroughs-Wellcome. Together, they pioneered a new approach to drug development, focusing on how compounds could inhibit the growth of cells.
Reflecting on her journey, Elion once said, “My grandfather died of cancer when I was 15. I wanted to help find a cure for such a terrible disease.” This personal loss fueled her determination.
Elion and Hitchings recognized that all living cells, especially fast-growing ones like cancer cells, rely on nucleic acids to multiply. They hypothesized that blocking the synthesis of these vital compounds could slow down or even stop cancer growth.
By 1950, they developed 6-mercaptopurine (6-MP), a compound that showed promise in lab tests. Over two years, they observed that it could inhibit leukemia cell growth in animals. A groundbreaking trial began in 1952, involving 107 patients, including many children facing dire diagnoses. Remarkably, some of the young patients entered remission, a significant hope compared to the previous lack of effective treatments.
There had been earlier chemotherapy options, but they were often highly toxic. In contrast, kids receiving 6-MP tolerated it better, with 15 children experiencing remission for varying lengths of time. According to Elion, “I was elated when the children got better, but crushed when they got sick again.”
Elion and Hitchings continued their research, looking for related compounds that could further improve remission. By the late 1950s, they developed a combination treatment using 6-MP and methotrexate, which showed better results for some patients.
Throughout her career, Elion went on to develop several vital drugs, including azathioprine for rheumatoid arthritis, acyclovir for viral infections, and AZT for HIV/AIDS. For her groundbreaking work, she received the Nobel Prize in 1988, alongside Hitchings and James Black.
Today, Elion’s legacy continues. According to recent statistics, there are over 1.9 million new cancer cases expected in the U.S. this year alone. The advancements she helped create have shaped modern cancer therapies, making treatment more effective and less harmful.
Elion’s story is not just about science but also about resilience and the pursuit of knowledge. Her journey reminds us that overcoming challenges can lead to incredible breakthroughs in health and medicine.
Source link
